Compliance & Validation — Documented
GxP validated, SOC 2 Type II, 21 CFR Part 11
Suvoda
Clinical trial technology company providing IRT/RTSM, eConsent, and eCOA for complex, patient-critical studies.
Suvoda, founded in 2013 and headquartered in Conshohocken, Pennsylvania, provides interactive response technology (IRT/RTSM) for randomization and trial supply management, along with eConsent and eCOA products, with a focus on complex, time-sensitive trials in areas such as oncology and rare disease. Its RTSM, eCOA, and eConsent services undergo annual SOC 2 Type 2 audits, and the company documents 21 CFR Part 11 compliance for its regulated trial systems.
- Headquarters
- Conshohocken, United States
- Founded
- 2013
- Compliance
- SOC 2 Type II, 21 CFR Part 11, GxP
- Deployment options
- cloud
- Website
- https://www.suvoda.com
- https://www.linkedin.com/company/suvoda
Categories
AI Use Cases
- Digital/Decentralized Trials
Vendor Scorecard
71% — Complete coverage. Coverage score — how completely Atlas documents Suvoda across 7 buyer-evaluation areas. Reflects available Atlas data, not solution quality.
Deployment & Hosting — Documented
cloud
Pricing Transparency — Not documented by Atlas
Ask the vendor: What is your pricing model, and what drives total cost of ownership?
Implementation & Onboarding — Not documented by Atlas
Ask the vendor: What is a realistic implementation timeline, and what onboarding support is included?
Organization & Role Fit — Documented
Mid-Size Biotech, Large Pharma, Top 20 Pharma, CRO / CDMO, Clinical Operations, Data Management
Solution Scope — Documented
Digital/Decentralized Trials
Company Viability — Documented
Private equity, $40.0M raised, Founded 2013
Always ask the vendor
Not captured in Atlas data — confirm directly. Excluded from the score above.
Data Rights & IP
Who owns model outputs? Is our proprietary data used to train models others can access, and where does our data reside?
Model Credibility & Explainability
Can you share validation studies or benchmarks, explain how the model reaches its conclusions, and describe how bias and drift are monitored?
Questions to Ask This Vendor
- How quickly can a mid-study protocol amendment be reflected in the IRT?
- How does the RTSM handle our randomization design and drug supply strategy?
- What does system validation and Part 11 documentation look like per study?
- How do eConsent and eCOA integrate with the IRT and our EDC?